Comparative Pharmacology
Head-to-head clinical analysis: DRAX EXAMETAZIME versus NEPHROFLOW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAX EXAMETAZIME versus NEPHROFLOW.
DRAX EXAMETAZIME vs NEPHROFLOW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAX EXAMETAZIME is a diagnostic radiopharmaceutical composed of technetium-99m (Tc-99m) labeled to exametazime (hexamethylpropyleneamine oxime, HMPAO). It passively diffuses across the blood-brain barrier and is rapidly converted to a hydrophilic complex, which is trapped in brain tissue. Distribution is proportional to regional cerebral blood flow, allowing SPECT imaging of cerebral perfusion.
NEPHROFLOW is a vasodilator that increases renal blood flow by selectively dilating afferent arterioles, leading to enhanced glomerular filtration rate (GFR). It also inhibits sodium reabsorption in the proximal tubule, promoting diuresis.
Adult: 5-20 mCi (185-740 MBq) administered intravenously as a single dose for brain imaging; dose is based on patient weight and imaging protocol.
NEPHROFLOW (Ioversol) 350 mg iodine/mL: 1 mL/kg intravenously up to 150 mL maximum for contrast imaging.
None Documented
None Documented
Terminal half-life is 6-8 hours; clinical context: allows for daily dosing in imaging studies.
4.2 hours (terminal) in normal renal function; prolongs in CKD.
Renal: 50-65% unchanged; fecal: 35-50% as metabolites; total renal elimination accounts for ~70% of dose, with 30% undergoing biliary excretion.
Primarily renal (85% unchanged); 15% biliary/fecal. In renal impairment, half-life doubles.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical